---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Ongoing post-approval monitoring"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Ongoing post-approval monitoring. Topics: Rare pediatric disease priority review voucher: post-approval report, Annual status reports on the postmarketing commitment, Adverse reaction reporting, and Real-world evidence generation planned by the manufacturer. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/ongoing-post-approval-monitoring"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Ongoing post-approval monitoring

<a id="heading-2.2.2.6"></a>

## 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

### Rare pediatric disease priority review voucher: post-approval report

> “The sponsor of an approved rare pediatric disease product application who is awarded a PRV must submit a report to FDA no later than 5 years after approval that addresses, for each of the first 4 post-approval years:”
> “the estimated population in the U.S. suffering from the rare pediatric disease for which the product was approved (both the entire population and the population aged 0 through 18 years)”
> “the actual amount of product distributed in the U.S.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-2"></a>

### Annual status reports on the postmarketing commitment

> “In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA.”

Source: [FDA NDA 220996 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220996Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-3"></a>

### Adverse reaction reporting

> “To report SUSPECTED ADVERSE REACTIONS, contact Mandos, LLC at 1-844-237-3600 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.2.2.6-4"></a>

### Real-world evidence generation planned by the manufacturer

> “Financing proceeds will support a comprehensive set of programs in anticipation of a potential approval and launch of adrabetadex that best provides access and meaningful support to the NPC community, including:”
> “Generating longitudinal real-world evidence and shared learning”

Source: [Beren Therapeutics financing press release (2026)](https://www.berentx.com/news/beren-secures-300m-financing-to-support-the-potential-commercial-launch-of-adrabetadex/)

<a id="topic-2.2.2.6-5"></a>

### Registered post-approval studies

No evidence found.

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
